Clinical Efficacy and Safety of T-DM1 for Patients with HER2-positive Breast Cancer

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Mar 26

PMID 27013890

Citations 5

Authors

Bo Ma

Qianqian Ma

Hongqiang Wang

Guolei Zhang

Huiying Zhang

Xiaohong Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to evaluate the therapeutic efficacy and safety of trastuzumab emtansine (T-DM1) for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer.

Methods: We performed a systemic review and meta-analysis of the relevant published clinical studies. A computerized search was performed for controlled clinical trials of T-DM1 in targeted treatment. Overall survival, progression-free survival, objective response rate, symptom progression free, and adverse events (AEs) were evaluated.

Results: Eight eligible trials with a total of 2,016 patients with breast cancer were included in the present meta-analysis. The treatment of patients with breast cancer with T-DM1 was associated with significantly increased overall and progression-free survival when compared with controls (P<0.0001). An analysis of the objective response rate and symptom progression free also demonstrated favorable results for T-DM1 treatment (P≤0.0001). There was no significant difference between the T-DM1 and control groups with respect to nonhematologic or hematologic AEs (P=0.99 and P=0.30, respectively).

Conclusion: Overall, T-DM1 is efficacious in the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer and low rates of AEs compared with controls.

Citing Articles

Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer.

Abdullah N, Al-Mansouri L, Ali N, Hadi N J Med Life. 2024; 16(11):1633-1638.

PMID: 38406785 PMC: 10893566. DOI: 10.25122/jml-2023-0163.

Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials.

Fu Z, Gao C, Xie J, Zhang C, Li S, Gu M BMC Cancer. 2023; 23(1):960.

PMID: 37817092 PMC: 10563201. DOI: 10.1186/s12885-023-11250-1.

HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells.

Xia L, Wen L, Qin Y, Dobson H, Zhang T, Comer F Cell Chem Biol. 2021; 28(5):610-624.e5.

PMID: 33711257 PMC: 8141015. DOI: 10.1016/j.chembiol.2021.02.013.

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic....

Johnston S, Hegg R, Im S, Park I, Burdaeva O, Kurteva G J Clin Oncol. 2017; 36(8):741-748.

PMID: 29244528 PMC: 7444639. DOI: 10.1200/JCO.2017.74.7824.

Development of Tc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer.

Rainone P, Riva B, Belloli S, Sudati F, Ripamonti M, Verderio P Int J Nanomedicine. 2017; 12:3447-3461.

PMID: 28496321 PMC: 5422330. DOI: 10.2147/IJN.S129720.

References

Yamamoto-Ibusuki M, Arnedos M, Andre F . Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Med. 2015; 13:137. PMC: 4462184. DOI: 10.1186/s12916-015-0369-5. View

Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J . Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91. PMC: 5125250. DOI: 10.1056/NEJMoa1209124. View

Perez E, Hurvitz S, Amler L, Mundt K, Ng V, Guardino E . Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res. 2014; 16(3):R50. PMC: 4229898. DOI: 10.1186/bcr3661. View

Michel L, Lorenzo Bermejo J, Gondos A, Marme F, Schneeweiss A . T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. Anticancer Res. 2015; 35(9):5085-90. View

Girish S, Gupta M, Wang B, Lu D, Krop I, Vogel C . Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012; 69(5):1229-40. PMC: 3337408. DOI: 10.1007/s00280-011-1817-3. View

Barok M, Tanner M, Koninki K, Isola J . Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011; 13(2):R46. PMC: 3219209. DOI: 10.1186/bcr2868. View

Yu Q, Zhu Z, Liu Y, Zhang J, Li K . Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. PLoS One. 2015; 10(5):e0127404. PMC: 4439018. DOI: 10.1371/journal.pone.0127404. View

Junutula J, Flagella K, Graham R, Parsons K, Ha E, Raab H . Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010; 16(19):4769-78. DOI: 10.1158/1078-0432.CCR-10-0987. View

Incorvati J, Shah S, Mu Y, Lu J . Targeted therapy for HER2 positive breast cancer. J Hematol Oncol. 2013; 6:38. PMC: 3703272. DOI: 10.1186/1756-8722-6-38. View

10.

Krop I, LoRusso P, Miller K, Modi S, Yardley D, Rodriguez G . A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012; 30(26):3234-41. DOI: 10.1200/JCO.2011.40.5902. View

11.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

12.

Singh J, Jhaveri K, Esteva F . HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer. 2014; 111(10):1888-98. PMC: 4229628. DOI: 10.1038/bjc.2014.388. View

13.

Peddi P, Hurvitz S . Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014; 6(5):202-9. PMC: 4206612. DOI: 10.1177/1758834014539183. View

14.

Diessner J, Bruttel V, Stein R, Horn E, Hausler S, Dietl J . Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis. 2014; 5:e1149. PMC: 3973200. DOI: 10.1038/cddis.2014.115. View

15.

Barok M, Joensuu H, Isola J . Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014; 16(2):209. PMC: 4058749. DOI: 10.1186/bcr3621. View

16.

Krishnamurti U, Silverman J . HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014; 21(2):100-7. DOI: 10.1097/PAP.0000000000000015. View

17.

Lewis Phillips G, Li G, Dugger D, Crocker L, Parsons K, Mai E . Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68(22):9280-90. DOI: 10.1158/0008-5472.CAN-08-1776. View

18.

Boyraz B, Sendur M, Aksoy S, Babacan T, Roach E, Kizilarslanoglu M . Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin. 2013; 29(4):405-14. DOI: 10.1185/03007995.2013.775113. View

19.

Miller K, Dieras V, Harbeck N, Andre F, Mahtani R, Gianni L . Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol. 2014; 32(14):1437-44. DOI: 10.1200/JCO.2013.52.6590. View

20.

Torres S, Maralani P, Verma S . Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. BMJ Case Rep. 2014; 2014. PMC: 4139549. DOI: 10.1136/bcr-2014-205680. View